Among high-risk patients with mild-to-moderate COVID-19, sotrovimab reduced the risk of disease progression. No safety signals were identified.

The results of this interim analysis of COMET-ICE indicate that sotrovimab can be a therapeutic agent for outpatients with Covid-19.

Notably, a 500-mg dose may also permit intramuscular administration, which may increase the convenience of and access to therapeutic antibody agents for patients with Covid-19.

Studies are currently under way to evaluate this route of administration.

Given its in vitro activity against variants of interest and concern, as well as its ability to neutralize other sarbecoviruses, we speculate that sotrovimab has the potential to remain therapeutically active even as SARS-CoV-2 continues to evolve.

Read More